In the government sector, cooperation agreements have been signed under the Productive Development Program (PDP) with the purpose of establishing a permanent structure of cooperation to perform activities related to policy of health, science and technology and industrial development. The entry of Fiocruz in the markets currently controlled by multinational companies - such as the use of monoclonal antibodies for cancer and rare diseases, autoimmune diseases, degenerative diseases, therapeutic vaccines, among others - increases the possibilities of establishing of partnerships for technology development and technology transfers, and the Brazil's competitiveness in the biotechnology sector.
From the assignment, by the Government of the State of Rio de Janeiro, of land of 570,000 m2 in the Industrial District of Santa Cruz, in the West Zone of Rio, Ministry of Health and Fiocruz formalize the construction of the New Final Processing Center of the Immunobiologicals Technology Institute (NCPFI of Biomanguinhos). The new project with an investment of Brazilian Real - R$ 800 million, will have adaptable and expansible platforms that allows to expand the production lines in order to quadruple the capacity of the final processing of vaccines t approximately 600 million doses per year. Considered a "green project", the industrial plant of Biomanguinhos will have panels for utilization of solar energy, reservoirs to capture rainwater, and a green belt surrounding the ground, encouraging local biodiversity.
Term of cooperation involving Fiocruz, the Ministry of Health and Ministry of Development, Industry and Foreign Trade, National Health Surveillance Agency (Anvisa) and National Institute of Metrology, Standardization and Industrial Quality (Inmetro) provide the development of activities related to industrial policy in the areas of prosthetics, new materials, drugs, hospital equipment and accreditation laboratories.
The cooperation between the National Institute for Quality Control in Health (INCQS) and Anvisa will facilitate the development of research to propose standards for the Brazilian pharmacopoeia, and taxonomic patterns and biochemical or genetic markers for the study of medicinal plants and certification and monitoring of chemical reference substances.
The Interinstitutional Program of Production and Innovation in Oncology, the fruit of a partnership with Fiocruz National Cancer Institute (Inca), provides the development of new drugs for the treatment and improve the quality of life for patients with cancer, the national production of drugs and diagnostic kits, assessment of public health programs, and interventions for prevention and health education. In addition, there are provided partnerships with national and international centers of research and technological development, referral hospitals in cancer, development and regulatory agencies, pharmaceutical industries, non-governmental organizations and sectoral policy actors.
See the catalog of the National Cooperation Agreements of Fiocruz (portuguese).